Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol 2022;23:758-767.
PMID: 35588752